{"id":"caspofungin-antifungal-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Pyrexia"},{"rate":"2-5%","effect":"Hypokalemia"},{"rate":"2-5%","effect":"Hypomagnesemia"},{"rate":"2-5%","effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to cell lysis and ultimately cell death. Caspofungin is a member of the echinocandin class of antifungal agents.","oneSentence":"Caspofungin inhibits the synthesis of beta-1,3-D-glucan, an essential component of fungal cell walls.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:09.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of invasive aspergillosis, invasive candidiasis, and esophageal candidiasis"}]},"trialDetails":[{"nctId":"NCT00748345","phase":"PHASE2, PHASE3","title":"Pharmacokinetics of Caspofungin in Burn Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-02","conditions":"Thermal Injury","enrollment":2},{"nctId":"NCT04368559","phase":"PHASE3","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mundipharma Research Limited","startDate":"2020-05-11","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":602},{"nctId":"NCT02805049","phase":"PHASE4","title":"Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-01-28","conditions":"Septic Shock, Peritonitis","enrollment":24},{"nctId":"NCT06907992","phase":"","title":"A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia","status":"NOT_YET_RECRUITING","sponsor":"Augusta University","startDate":"2025-05-01","conditions":"Candidemia","enrollment":150},{"nctId":"NCT06892951","phase":"PHASE1, PHASE2","title":"CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2025-06","conditions":"Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections","enrollment":100},{"nctId":"NCT03580733","phase":"PHASE3","title":"Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2019-01-01","conditions":"ICU Yeast Intra-abdominal Infection","enrollment":448},{"nctId":"NCT06137690","phase":"","title":"Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients","status":"UNKNOWN","sponsor":"People's Hospital of Zhengzhou University","startDate":"2018-07-01","conditions":"Invasive Fungal Infection","enrollment":550},{"nctId":"NCT01288378","phase":"PHASE3","title":"Empirical Versus Preemptive Antifungal Therapy","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2012-03","conditions":"Fungal Infection, Leukemia, Myelodysplastic Syndromes","enrollment":556},{"nctId":"NCT03667690","phase":"PHASE3","title":"Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2018-10-07","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":199},{"nctId":"NCT04004078","phase":"","title":"An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM","status":"COMPLETED","sponsor":"People's Hospital of Zhengzhou University","startDate":"2018-03-01","conditions":"Invasive Fungal Infection","enrollment":314},{"nctId":"NCT01869829","phase":"","title":"PEACE: Pediatric Antifungal Comparative Effectiveness","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-01","conditions":"Pediatric Invasive Candidiasis","enrollment":750},{"nctId":"NCT02734862","phase":"PHASE2","title":"CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2016-07-26","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":207},{"nctId":"NCT04502771","phase":"","title":"Therapeutic Drug Monitoring of Antifungals in Intensive Care Units","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-01-01","conditions":"Intensive Care Unit Patients","enrollment":200},{"nctId":"NCT02895529","phase":"PHASE4","title":"A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy","status":"TERMINATED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2016-11-30","conditions":"Hematologic Neoplasms","enrollment":61},{"nctId":"NCT03798600","phase":"","title":"Pharmacokinetics/Pharmacodynamics (PK/PD) of Caspofungin in Intensive Care Unit (ICU) Patients. An Open Observational Study for Antifungal Treatment's Optimization","status":"COMPLETED","sponsor":"Careggi Hospital","startDate":"2016-01-01","conditions":"Critical Illness, Infection","enrollment":20},{"nctId":"NCT02856178","phase":"PHASE1, PHASE2","title":"Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients","status":"WITHDRAWN","sponsor":"F2G Biotech GmbH","startDate":"2017-04-20","conditions":"Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT00250432","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":"Invasive Candidiasis","enrollment":204},{"nctId":"NCT02941068","phase":"PHASE2","title":"the Influence of Prophylactic and Empirical Anti-fungal Treatment in Severe Sepsis Patients With Perforations","status":"COMPLETED","sponsor":"Nanjing PLA General Hospital","startDate":"2012-03","conditions":"Intra-abdominal Perforation","enrollment":223},{"nctId":"NCT00076869","phase":"PHASE2","title":"MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-01","conditions":"Aspergillosis","enrollment":55},{"nctId":"NCT00105144","phase":"PHASE3","title":"Study of Micafungin in Patients With Invasive Candidiasis or Candidemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-09","conditions":"Candidiasis, Candidemia","enrollment":611},{"nctId":"NCT00982540","phase":"NA","title":"Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients","status":"TERMINATED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2010-02","conditions":"Invasive Fungal Infections, Invasive Aspergillosis, Invasive Fusariosis","enrollment":28},{"nctId":"NCT00723073","phase":"","title":"Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-01","conditions":"Febrile Neutropenia","enrollment":323},{"nctId":"NCT00005920","phase":"PHASE2","title":"Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":"Candidiasis, Oral, HIV Infections","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"caspofungin antifungal therapy","genericName":"caspofungin antifungal therapy","companyName":"Centre Hospitalier Universitaire, Amiens","companyId":"centre-hospitalier-universitaire-amiens","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Caspofungin inhibits the synthesis of beta-1,3-D-glucan, an essential component of fungal cell walls. Used for Treatment of invasive aspergillosis, invasive candidiasis, and esophageal candidiasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}